Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy

What Was Tested

The trial (not phased) is built around Oxytocin.

It had two arms (groups): Group (A) (experimental) and Group (B) (placebo comparator).

Patients will be given uterotonics.

Patients will not be given uterotonics.

The registry classes the interventions as drug and other.

Who Took Part

Enrollment: 70 planned participants were the target.

It was open to women only aged from 20 years up to 40 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Pregnancy of singleton living fetus. Previous one or more cesarean sections. Gestational age: \> 32 weeks. The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity". Preoperative hemoglobin more than 10 gm/dl.

The full record lists 6 inclusion and 5 exclusion criteria; among the exclusions: maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.…; any known or reported hypersensitivity to the used medication; all cases with spontaneous placental separation at laparotomy.

How the Study Was Run

The set-up was randomized, parallel-group and triple-blind.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Oxytocin group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Oxytocin, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, investigator and outcomes assessor.

It started in 2024-07-01 with completion listed for 2024-12-31.

It ran at 1 site in Egypt.

Its stated primary purpose is prevention.

What Was Measured

Researchers chose this as the main measure: Intraoperative blood loss (time frame: during operation).

It also tracked 1 secondary outcome, for example operative time.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Oxytocin in 70 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Oxytocin compound page, all human trials.